Embecta Corp. (EMBC) Research

Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.

Market snapshot

Symbol
EMBC
Price
$3.11
Day change
+0.65%
Market cap
$184.5M
P/E ratio
1.62x
52-week range
2.77-15.55
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Next earnings
in 2 months
Analyst price target
$5.00

Peer companies

  • Aquestive Therapeutics, Inc. (AQST)
  • CareDx, Inc (CDNA)
  • Emergent BioSolutions Inc. (EBS)
  • Evolent Health, Inc. (EVH)
  • Maravai LifeSciences Holdings, Inc. (MRVI)
  • Myriad Genetics, Inc. (MYGN)
  • Prime Medicine, Inc. (PRME)
  • Personalis, Inc. (PSNL)

Recent insider activity

  • Roth Anthony M. — A-Award (30000 shares) on 2026-06-01
  • Anderson Carrie L — A-Award (22841 shares) on 2026-02-11
  • HOMBACH ROBERT J. — A-Award (22841 shares) on 2026-02-11
  • Morris Milton Mayo — A-Award (22841 shares) on 2026-02-11
  • Prange Karen — A-Award (22841 shares) on 2026-02-11

Open Embecta Corp. (EMBC) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.